BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND NTRK3, TRKC, 4916, ENSG00000140538, Q16288, gp145 trkC
85 results:

  • 1. Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.
    Santi I; Vellekoop H; M Versteegh M; A Huygens S; Dinjens WNM; Mölken MR
    Mol Diagn Ther; 2024 May; 28(3):319-328. PubMed ID: 38616205
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A novel EML4-ntrk3 fusion in lung adenocarcinoma with dramatic response to entrectinib.
    Batra U; Nathany S; Sharma M; Jain P; Mehta A; Bansal A
    J Cancer Res Ther; 2023 Oct; 19(7):2045-2047. PubMed ID: 38376315
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Repotrectinib: First Approval.
    Dhillon S
    Drugs; 2024 Feb; 84(2):239-246. PubMed ID: 38279972
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. ETV6::ntrk3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report.
    Gao L; Ai X; Lu S
    Lung Cancer; 2024 Jan; 187():107443. PubMed ID: 38113652
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Detection of NTRK fusions by RNA-based nCounter is a feasible diagnostic methodology in a real-world scenario for non-small cell lung cancer assessment.
    de Oliveira Cavagna R; de Andrade ES; Tadin Reis M; de Paula FE; Noriz Berardinelli G; Bonatelli M; Ramos Teixeira G; Garbe Zaniolo B; Mourão Dias J; da Silva FAF; Baston Silva CE; Xavier Reis M; Lopes Maia E; de Alencar TS; Jacinto AA; da Nóbrega Oliveira REN; Molina-Vila MA; Ferro Leal L; Reis RM
    Sci Rep; 2023 Dec; 13(1):21168. PubMed ID: 38036758
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations.
    Shang X; Zhang W; Han W; Xia H; Liu N; Wang X; Liu Y
    BMC Pulm Med; 2023 Nov; 23(1):482. PubMed ID: 38031067
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
    Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
    Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Cost-Efficient Detection of
    Romanko AA; Mulkidjan RS; Tiurin VI; Saitova ES; Preobrazhenskaya EV; Krivosheyeva EA; Mitiushkina NV; Shestakova AD; Belogubova EV; Ivantsov AO; Iyevleva AG; Imyanitov EN
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762506
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A Detailed Histologic and Molecular Assessment of the Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma.
    Chou A; Qiu MR; Crayton H; Wang B; Ahadi MS; Turchini J; Clarkson A; Sioson L; Sheen A; Singh N; Clifton-Bligh RJ; Robinson BG; Gild ML; Tsang V; Leong D; Sidhu SB; Sywak M; Delbridge L; Aniss A; Wright D; Graf N; Kumar A; Rathi V; Benitez-Aguirre P; Glover AR; Gill AJ
    Mod Pathol; 2023 Dec; 36(12):100329. PubMed ID: 37716505
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. NTRK fusions in solid tumours: what every pathologist needs to know.
    Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
    Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Congenital peribronchial myofibroblastic tumor (CPMT): a case report with long term follow-up and next-generation sequencing (NGS).
    Zhou P; Li S; Wang W; Tang Y; Jiang L
    BMC Pediatr; 2023 Apr; 23(1):184. PubMed ID: 37081446
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Spectrum of kinase gene rearrangements in a large series of paediatric inflammatory myofibroblastic tumours.
    Preobrazhenskaya EV; Suleymanova AM; Bizin IV; Zagrebin FA; Romanko AA; Saitova ES; Mulkidzhan RS; Imyanitov EN
    Histopathology; 2023 Jul; 83(1):109-115. PubMed ID: 37071060
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Diffuse pulmonary meningotheliomatosis with pan-TRK expression by immunohistochemistry: a novel finding and potential pitfall.
    Karakas C; Nead MA; Velez MJ
    Diagn Pathol; 2023 Feb; 18(1):22. PubMed ID: 36782261
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Frequently mutated genes in predicting the relapse of stage I lung adenocarcinoma.
    Rao W; Yang L; Dai N; Zhang L; Liu J; Yang B; Li M; Shan J; Wang Q; Wang D
    Clin Transl Oncol; 2023 Jun; 25(6):1767-1778. PubMed ID: 36739576
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. CANTRK: A Canadian Ring Study to Optimize Detection of NTRK Gene Fusions by Next-Generation RNA Sequencing.
    Stockley TL; Lo B; Box A; Corredor AG; DeCoteau J; Desmeules P; Feilotter H; Grafodatskaya D; Greer W; Hawkins C; Huang WY; Izevbaye I; Lépine G; Martins Filho SN; Papadakis AI; Park PC; Riviere JB; Sheffield BS; Spatz A; Spriggs E; Tran-Thanh D; Yip S; Zhang T; Torlakovic E; Tsao MS
    J Mol Diagn; 2023 Mar; 25(3):168-174. PubMed ID: 36586421
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.
    Wang Z; Ge Y; Li H; Fei G; Wang S; Wei P
    Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36305643
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
    Chow YP; Zainul Abidin N; Kow KS; Tho LM; Wong CL
    PLoS One; 2022; 17(10):e0276161. PubMed ID: 36256645
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Metastatic triple negative breast cancer with NTRK gene fusion on tissue but not on ctDNA molecular profile.
    Singh N; Singh R; Decker B; Robins D; Vidal G
    BMJ Case Rep; 2022 Oct; 15(10):. PubMed ID: 36223973
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Prevalence of NTRK Fusions in Canadian Solid Tumour cancer Patients.
    Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
    Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Genomic Landscapes and Hallmarks of Mutant RAS in Human cancers.
    Scharpf RB; Balan A; Ricciuti B; Fiksel J; Cherry C; Wang C; Lenoue-Newton ML; Rizvi HA; White JR; Baras AS; Anaya J; Landon BV; Majcherska-Agrawal M; Ghanem P; Lee J; Raskin L; Park AS; Tu H; Hsu H; Arbour KC; Awad MM; Riely GJ; Lovly CM; Anagnostou V
    Cancer Res; 2022 Nov; 82(21):4058-4078. PubMed ID: 36074020
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.